Bliss GVS picks new CEO as Anupam Rasayan era begins
Rahul Adakmol, ex-Dr. Reddy's executive, takes charge from July 2026. Current CEO Narsimha Kamath stays on as MD during transition.
What's new
- Rahul Adakmol appointed CEO effective 15 July 2026, replacing Narsimha Kamath.
- Kamath steps down as CEO but remains managing director.
- Santosh Parab, former independent director, appointed additional non-executive non-independent director.
Why this matters
This CEO change is the first visible management shift after Anupam Rasayan's 43.3% stake buy. With a new promoter and a new CEO from a large-pharma background, the company is signalling a strategic pivot. Kamath's continued presence as MD provides some continuity, but the real test is whether Adakmol's appointment aligns operational priorities with the incoming promoter's vision.
What we're watching
- Any strategic shifts or restructuring under Adakmol's leadership.
- Integration with Anupam Rasayan's business and potential combined operations.
- Kamath's role as MD and whether he remains involved in day-to-day operations.
The full read
Bliss GVS Pharma is getting a new CEO, and the timing is no coincidence. The board appointed Rahul Adakmol to take charge from 15 July 2026, replacing Narsimha Kamath who steps down as CEO but stays on as managing director. Adakmol brings a pedigree from Dr. Reddy's, Bharat Serums, and Reliance — experience that fits a company now under the control of Anupam Rasayan, which bought a 43.3% stake last year. The two-year runway before the switch gives Kamath room to hand over smoothly, and his continued presence as MD offers some stability. But the message is clear: the new promoter wants its own leadership in place. For a mid-cap pharma with ₹5,217 crore market cap and trailing PAT growth of 122%, the next strategic direction will be closely watched. The open question is what strategic priorities Adakmol will pursue once in the driver's seat.
Questions answered
- When does Rahul Adakmol take over as CEO?
- Adakmol's appointment as CEO is effective from 15 July 2026. The transition is more than two years away, allowing for a planned handover.
- What happens to Narsimha Kamath after stepping down as CEO?
- Kamath remains managing director of the company. He is expected to ensure a smooth handover and continue in a strategic role on the board.
- What is Adakmol's background?
- Adakmol is a chemical engineer and IIM Bangalore alumnus with over 22 years of experience, including senior roles at Dr. Reddy's Laboratories, Bharat Serums and Vaccines, and Reliance Industries.
- How does this relate to the recent ownership change?
- Anupam Rasayan acquired a 43.3% stake and completed an open offer, gaining control. This CEO appointment is the first major management move under the new ownership structure.
- Who is Santosh Parab and what is his new role?
- Santosh Parab, previously an independent director, has been appointed as an additional non-executive non-independent director, likely to strengthen the board under the new promoter.